Next Article in Journal
Synthesis, Structure and Biological Activity of CIA and CIB, Two α-Conotoxins from the Predation-Evoked Venom of Conus catus
Next Article in Special Issue
Botulinum Toxin for Central Neuropathic Pain
Previous Article in Journal
Leukotoxin of Bibersteinia trehalosi Contains a Unique Neutralizing Epitope, and a Non-Neutralizing Epitope Shared with Mannheimia haemolytica Leukotoxin
Previous Article in Special Issue
The Expanding Therapeutic Utility of Botulinum Neurotoxins
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle
Toxins 2018, 10(6), 221; https://doi.org/10.3390/toxins10060221

Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine

1
Department of Neurology, Nimes University Hospital, 30900 Nimes, France
2
Neurological Institute, Foundation Casimiro Mondino, 27100 Pavia, Italy
*
Author to whom correspondence should be addressed.
Received: 16 April 2018 / Revised: 28 May 2018 / Accepted: 28 May 2018 / Published: 1 June 2018
Full-Text   |   PDF [2108 KB, uploaded 1 June 2018]   |  

Abstract

Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX® (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN® (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2–13) and 21 (6–68) months, respectively. From baseline to first injection, 44 patients (73%) had >50% reduction in frequency of migraine episodes, 29 patients (48%) showed >50% reduction in number of headache days, and 28 patients (46%) had a >50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN® thus seems to represent an effective and sustained prophylactic treatment of chronic migraine. View Full-Text
Keywords: refractory chronic migraine; tension headache; medication overuse headache; prophylactic treatment; XEOMIN® refractory chronic migraine; tension headache; medication overuse headache; prophylactic treatment; XEOMIN®
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ion, I.; Renard, D.; Le Floch, A.; De Verdal, M.; Bouly, S.; Wacongne, A.; Lozza, A.; Castelnovo, G. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine. Toxins 2018, 10, 221.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top